Q-omics provides the consensus-scored TRAJ37 profile across patient tissues and cancer cell-line models. TRAJ37 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, TRAJ37 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, TRAJ37 RNA expression shows 13,641 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight THCA, STAD, and LSCC as cancer lineages where TRAJ37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ37 survival associations across molecular data types. TRAJ37 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ37 RNA expression–survival associations across cancer types. High TRAJ37 expression shows unfavorable associations in THCA, MESO, TGCT and GBM, but favorable associations in STAD and SKCM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for TRAJ37 RNA expression.
This table summarizes TRAJ37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ37 shows higher tumor expression in STAD, KIRC and ESCA. The STAD box plot shows higher TRAJ37 RNA expression in tumor versus normal tissue (log2 FC = +0.463, t-test p = .010).
This table shows molecular features associated with TRAJ37 in patient tissues and cancer cell lines. In patient samples, TRAJ37 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
